Members

Immunofyx

ImmunoFyx is a private early-stage biotechnology company focused on novel antibody fusion proteins targeting highly metastatic solid tumours. Up to 90% of cancer deaths are associated with metastases for which there are few treatment options.  ImmunoFyx utilizes unique combinations of endogenous anti-cancer proteins to reduce tumour growth, angiogenesis and metastases.

Contact Info

31 Bunton Court Winnipeg R3X 1K4 MB
P: 431-777-7759
E: mark@immunofyx.com

member

Back